Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
Rhea-AI Summary
Axogen (Nasdaq: AXGN) will report first quarter 2026 financial results on April 28, 2026. Management will host an investor conference call and webcast at 8:00 a.m. ET after the release.
Investors can join by phone or listen to a live webcast; an archived replay and presentation slides will be available on the company's Investors page at www.axogeninc.com.
Positive
- None.
Negative
- None.
News Market Reaction – AXGN
In the Apr 14 session, AXGN gained 2.96%, reflecting a moderate positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Earnings date notice | Neutral | +1.7% | Announced date and call details for Q4 and full-year 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date scheduling news was followed by a modest +1.71% move, suggesting a historically mild reaction to this type of announcement.
Recent news for Axogen highlights capital markets activity, earnings, and outreach. In January 2026, Axogen announced and priced a public offering, which coincided with single‑digit percentage declines. The February 24, 2026 earnings release showed strong revenue growth and BLA approval but saw an -8.14% move. An earlier earnings date notice on February 10, 2026 coincided with a modest gain. The current earnings-date announcement fits this pattern of routine communications around financial reporting.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALACHUA, Fla. and TAMPA, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the first quarter of 2026 on Tuesday, April 28, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available on the Investors page of the company's website at www.axogeninc.com.
About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
